Disparities in stage at diagnosis among breast cancer molecular subtypes in China
Zeng H, Wu S, Ma F, Ji J, Lu L, Ran X, Shi J, Li D, An L, Zheng R, Zhang S, Chen W, Wei W, He Y, He J. Disparities in stage at diagnosis among breast cancer molecular subtypes in China. Cancer Medicine 2023, 12: 10865-10876. PMID: 36951474, PMCID: PMC10225199, DOI: 10.1002/cam4.5792.Peer-Reviewed Original ResearchConceptsBody mass indexBreast cancerMolecular subtypesMass indexFamily historyFirst primary invasive breast cancerFirst primary breast cancerPrimary invasive breast cancerHuman epidermal growth factor receptor 2Early-stage breast cancerEpidermal growth factor receptor 2Triple-negative breast cancerBreast cancer molecular subtypesEnd Results (SEER) databaseBreast cancer treatment strategiesGrowth factor receptor 2Primary breast cancerInvasive breast cancerOverweight/obeseStage breast cancerBreast cancer patientsBreast cancer casesCancer molecular subtypesFactor receptor 2Cancer treatment strategiesDisparities in stage at diagnosis for liver cancer in China
Shan T, Ran X, Li H, Feng G, Zhang S, Zhang X, Zhang L, Lu L, An L, Fu R, Sun K, Wang S, Chen R, Li L, Chen W, Wei W, Zeng H, He J. Disparities in stage at diagnosis for liver cancer in China. Journal Of The National Cancer Center 2023, 3: 7-13. PMID: 39036312, PMCID: PMC11256694, DOI: 10.1016/j.jncc.2022.12.002.Peer-Reviewed Original ResearchLiver cancerStage IIIStage distributionHospital-based studyProportion of patientsLiver Cancer stagePrimary liver cancerCancer control policiesCancer awarenessCancer stageTreatment strategiesFamily historyStudy populationStage ISocioeconomic populationsCancerLogistic regressionPatientsDiagnosisEarly detectionHigher proportionDifferent populationsPopulationProportionHospital